文献速递妇科

HPV 16/18感染对接受根治性放(化)疗的局部晚期宫颈癌临床结局的影响——一项前瞻性观察性研究

Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study.
PubMed 文献 · Gynecol Oncol · 2017-12-06

本研究前瞻性纳入2010年5月至2012年4月接受根治性放(化)疗的150例组织学确诊宫颈癌患者,最终分析135例。治疗前HPV16/18 DNA阳性126例(93%),随访中病毒载量显著下降(p<0.0001),但9个月时89例(66%)持续感染;持续感染者总体复发和局部区域复发均显著高于清除者。

要点

  • 治疗前HPV16/18 DNA阳性126/135例(93%),其中HPV-16占91%。
  • 随访中病毒载量显著下降(p<0.0001),但9个月时89/135例(66%)持续感染。
  • 持续感染者总体复发44/89(49%)、局部区域复发29/89(32%),高于清除者12/43(28%)和5/43(11%)。

核心结论

  • 在接受根治性放(化)疗的局部晚期宫颈癌中,治疗后近期HPV 16/18持续感染率显著较高,且与更高的局部区域复发、总体复发相关,并与早期复发相关。

研究设计与样本

  • 前瞻性观察性研究,2010年5月至2012年4月纳入150例组织学确诊并接受根治性放(化)疗的宫颈癌患者,最终135例纳入分析。
  • 治疗前、治疗结束时及每3个月至24个月采集宫颈活检/刷检,采用实时聚合酶链反应(RT-PCR)定量检测HPV 16/18,并与临床终点相关分析。

主要发现

  • 治疗前HPV16/18 DNA检出126/135例(93%),其中HPV-16占91%。
  • 治疗前HPV-16和HPV-18平均log(±SD)病毒载量分别为4.76(±2.5)和0.14(±2.1)拷贝/10ng DNA。
  • 随访中病毒载量显著下降(p<0.0001);至9个月随访时89/135例(66%)持续HPV感染。
  • 9个月时持续HPV 16/18感染者总体复发44/89(49%)、局部区域复发29/89(32%),HPV清除者分别为12/43(28%)和5/43(11%),p=0.024和p=0.02。
  • 24个月时持续HPV感染对局部区域控制(LRC)和无复发生存(RFS)有显著影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: With an aim to investigate the impact of Human Papilloma Virus (HPV) 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy, we undertook this prospective study. METHODS: Between May 2010 and April 2012, 150 histologically proven cervical cancer patients treated with radio (chemo) therapy were accrued. Cervical biopsies/brushings were collected at pre-treatment, end of treatment and at 3 monthly intervals up to 24months. Quantitative estimation of HPV 16/18 was done using real-time polymerase chain reaction (RT-PCR) and correlated with various clinical end-points. RESULTS: Out of 150 patients accrued, 135 patients were considered for final analysis. Pre-treatment HPV16/18 DNA was detected in 126 (93%) patients, with HPV-16 present in 91%. The mean log (±SD) HPV-16 and HPV-18 viral load at pre-treatment was 4.76 (±2.5) and 0.14 (±2.1) copies/10ng of DNA, respectively. Though significant decline in viral load was observed on follow-ups (p<0.0001); by 9-month follow-up, 89 (66%) patients had persistence of HPV infection. Patients with persistent HPV 16/18 infection had a significantly higher overall and loco-regional relapses [44/89 (49%) and 29/89 (32%)] as compared to HPV clearance by 9months [12/43 (28%) and 5/43 (11%)] with p=0.024 and p=0.02, respectively. Also, persistent HPV infection by 24-month showed a significant impact on loco-regional control (LRC) and recurrence-free survival (RFS). CONCLUSION: In locally advanced cervical cancers treated with radical radio (chemo) therapy, persistent HPV 16/18 infection is significantly high in immediate post-treatment period and correlated with higher loco-regional, overall relapses and was also associated with early relapses.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mahantshetty U, Teni T, Naga P, et al. Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study. Gynecol Oncol. 2017. PMID: 29203175. doi:10.1016/j.ygyno.2017.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。